Join        Login             Stock Quote

Unique treatment for type 2 diabetes offers advance in disease management

Wednesday, May 26, 2010 9:02 AM

Health Canada approves Victoza(R), the first human GLP-1 analogue, to help people with type 2 diabetes maintain control of their disease Diabetes is growing at an alarming rate in Canada, with an estimated 3.7 million people expected to be diagnosed by 2020.(1) It is a progressive disease that, if not properly monitored and managed over time, will lead to serious long term complications. Canadians now have a novel treatment available to help them maintain optimal blood glucose levels. Health Canada has approved Victoza(R) (liraglutide), the first GLP-1 analogue, for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with metformin or metformin and a sulfonylurea.(2)

Victoza(R) works to mimic the body's natural response to food by stimulating the release of insulin only when blood glucose levels are high. In people with type 2 diabetes, Victoza(R) has been proven to lower blood glucose as well as weight and blood pressure more effectively than other diabetes therapies.(3),(4),(5),(6),(7),(8) Weight loss with Victoza(R) is attributed to the fact that it slows gastric emptying and leads to increased satiety after meals. Victoza(R) is naturally broken down in the body and does not require renal excretion.

"Despite our best efforts, many Canadians with type 2 diabetes are unable to achieve the recommended level of diabetes control with current therapies," says Dr. Bernard Zinman, Director, Leadership Sinai Centre for Diabetes, Professor of Medicine, University of Toronto. "This is of great concern since poor diabetes control increases the risk of developing serious long term complications, such as blindness, amputations, cardiovascular disease and kidney disease. Maintaining target glucose levels is an important aspect of managing diabetes, and with Victoza(R), patients have a new treatment option to help them achieve this goal."

People with type 2 diabetes do not properly produce or use GLP-1, meaning they have a GLP-1 impairment. When this happens, GLP-1 does not stimulate beta cells that lead to insulin production, impacting the body's ability to properly metabolise food and maintain optimal blood glucose levels.(9)

Victoza(R) is a GLP-1 analogue that is 97 per cent similar to the natural human hormone GLP-1 produced by the human body.(4) Victoza(R) mimics the GLP-1 effect in people who do not produce enough or use their own GLP-1.4

"I was diagnosed with type 2 diabetes 25 years ago," explains Ram Krishna, a diabetes patient. "People don't realize the day-to-day physical and financial challenges that are involved with managing the disease.


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.